Effect of Online Training on the Reliability of Assessing Sacroiliac Joint Radiographs in Axial Spondyloarthritis: A Randomized, Controlled Study (2024)
https://pubmed.ncbi.nlm.nih.gov/39278654/

Validation of SPARCC MRI-RETIC e-tools for increasing scoring proficiency of MRI sacroiliac joint lesions in axial spondyloarthritis (2024)
https://pubmed.ncbi.nlm.nih.gov/38351052/

Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry (2023)
https://pubmed.ncbi.nlm.nih.gov/38053462/

Impact of sex on spinal radiographic progression in axial spondyloarthritis: a longitudinal Swiss cohort analysis over a period of 10 years (2023)
https://pubmed.ncbi.nlm.nih.gov/37507208/

Obesity Represents a Persisting Health Issue in Axial Spondyloarthritis, Particularly Affecting Socially Disadvantaged Patients (2023)
https://pubmed.ncbi.nlm.nih.gov/37453738/

Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry (2023)
https://pubmed.ncbi.nlm.nih.gov/37289315/

Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry (2023)
https://pubmed.ncbi.nlm.nih.gov/37277211/

Site-specific assessment of spinal radiographic progression improves detection of TNF blocker-associated disease modification in axial spondyloarthritis: longitudinal observational data from the Swiss Clinical Quality Management Registry (2023)
https://pubmed.ncbi.nlm.nih.gov/36915202/

HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry (2023)
https://pubmed.ncbi.nlm.nih.gov/36574181/

Sacroiliac joint radiographic progression in axial spondyloarthritis is retarded by the therapeutic use of TNF inhibitors: 12-year data from the SCQM registry (2022)
https://pubmed.ncbi.nlm.nih.gov/36270744/

Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort (2022)
https://pubmed.ncbi.nlm.nih.gov/35110365/

Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort (2022)
https://pubmed.ncbi.nlm.nih.gov/33036663/

Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort (2020)
https://pubmed.ncbi.nlm.nih.gov/32581090/

Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort (2020)
https://pubmed.ncbi.nlm.nih.gov/32196530/

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis (2019)
https://pubmed.ncbi.nlm.nih.gov/31145730/

Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort (2018)
https://pubmed.ncbi.nlm.nih.gov/29449504/

TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort (2018)
https://pubmed.ncbi.nlm.nih.gov/28939631/

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis (2017)
https://pubmed.ncbi.nlm.nih.gov/28724442/